# BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer

Source: https://onco.cc/ideas/idea-atc-triplet-io/  
OnCo record `idea-atc-triplet-io` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Add immunotherapy to the two targeted pills in the most aggressive thyroid cancer, because the combination has produced multi-year survivors in early series.

## Summary

The idea is to make dabrafenib and trametinib plus pembrolizumab the standard first-line treatment for BRAF V600E-mutant anaplastic thyroid cancer. Anaplastic thyroid cancer is immunologically hot relative to differentiated cancers, with high PD-L1 expression and mutational burden, and targeted therapy induces rapid antigen release that checkpoint blockade can exploit. MD Anderson series of the triplet report multi-year survivors and longer overall survival than the doublet, building on the anaplastic cohort of the ROAR trial. The hypothesis is that adding pembrolizumab extends overall survival; given the rarity of the disease, the test is an international randomised phase 2 of doublet versus triplet with survival at one year as primary endpoint.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: Adding pembrolizumab to dabrafenib-trametinib extends OS in BRAF V600E ATC.
- Rationale: Targeted therapy induces rapid immunogenic response and antigen release; ATC is immunologically hot relative to differentiated cancers.
- Proposed test: International randomised phase 2 (doublet vs triplet) given rarity, with OS at 12 months as primary endpoint.
- Maturity: early-clinical

## Sources

- ClinicalTrials.gov NCT02034110: ROAR (anaplastic thyroid cancer cohort): https://clinicaltrials.gov/study/NCT02034110

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- targets: [BRAF](https://onco.cc/targets/braf/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- trials: [ROAR (anaplastic thyroid cancer cohort)](https://onco.cc/trials/roar-atc/)
- key papers: [BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications](https://onco.cc/key-papers/paper-braf-thyroid-endocr-rev-2007/), [BRAF mutation in thyroid cancer](https://onco.cc/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/), [Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations](https://onco.cc/key-papers/paper-braf-thyroid-n-engl-j-med-2015/)

---
JSON: https://onco.cc/api/v1/entities/idea-atc-triplet-io.json